Zhuo Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuo Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Zhen Fan
Tongji University 4800 Caoan Road
3 shared publications - Jianzhong Du
East China University of Science and Technology
2 shared publications - Jinlong Qin
Department of Obstetrics and Gynecology, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications - Mingchen Lv
Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China
2 shared publications - Yaping Liu
Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China
2 shared publications Fan Zhang
1 shared publication
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
Amino acid-improved bovine serum albumin microbubbles for the focused ultrasound-mediated drug delivery and attenuation of α-synuclein fibrils
The misfolded and aggregation of αsyn are considered one of the culprits of Parkinson’s disease (PD), yet existing clinical therapies are still limited in the efficacy. Herein, the strategy of the microbubbles combined with focused ultrasound was employed to open the blood brain barrier for fast drug delivery into the brain. Specifically, the bovine serum albumin microbubbles (MBs) with excellent stability were produced through improved preparation method as well as introduction of L-glutamic acid. The stability of concentration and diameter were increased by 4.3 and 2.0 times than traditional method, respectively. Meanwhile, quinones, dipeptide HY and fluorescence dye Cy7 were conjugated together (DNHY-Cy7) for the interference of α-syn aggregation and imaging. The results indicate that DNHY was able to attenuate α-syn fibrils, α-syn fibrillization and the amount of α-syn fibrils are gradually reduced by 59.3% and 69.4%, respectively, which additionally reducing α-syn fibrils induced ROS, mitochondrial and membrane damage. Importantly, the MBs carried with DNHY-Cy7 (MBs@DNHY-Cy7) were able to open the blood brain barrier with the irradiation of focused ultrasound within 2 min, thus the delivery and accumulation of DNHY-Cy7 into the brain were achieved, which may present a promising strategy for α-syn related PD therapy.
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAmino acid-improved bovine serum albumin microbubbles for the focused ultrasound-mediated drug delivery and attenuation of α-synuclein fibrils
The misfolded and aggregation of αsyn are considered one of the culprits of Parkinson’s disease (PD), yet existing clinical therapies are still limited in the efficacy. Herein, the strategy of the microbubbles combined with focused ultrasound was employed to open the blood brain barrier for fast drug delivery into the brain. Specifically, the bovine serum albumin microbubbles (MBs) with excellent stability were produced through improved preparation method as well as introduction of L-glutamic acid. The stability of concentration and diameter were increased by 4.3 and 2.0 times than traditional method, respectively. Meanwhile, quinones, dipeptide HY and fluorescence dye Cy7 were conjugated together (DNHY-Cy7) for the interference of α-syn aggregation and imaging. The results indicate that DNHY was able to attenuate α-syn fibrils, α-syn fibrillization and the amount of α-syn fibrils are gradually reduced by 59.3% and 69.4%, respectively, which additionally reducing α-syn fibrils induced ROS, mitochondrial and membrane damage. Importantly, the MBs carried with DNHY-Cy7 (MBs@DNHY-Cy7) were able to open the blood brain barrier with the irradiation of focused ultrasound within 2 min, thus the delivery and accumulation of DNHY-Cy7 into the brain were achieved, which may present a promising strategy for α-syn related PD therapy.
- Open Access
- 28 August 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4346-4360
A Metal-Peptide Framework as a Nanozyme for the Attenuation of Amyloid-β Aggregation and Reactive Oxygen Species
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by abnormal performance in memory, cognition, and language, and it imposes a heavy economic burden worldwide. Amyloidosis and oxidative stress are highly associated with AD progression, yet limited clinical drugs are available at present. Nanozymes exhibit diverse enzyme-mimetic activities and have attracted widespread attention as a promising alternative candidate for scavenging reactive oxygen species to maintain the oxidation–antioxidation balance in cells. Neurotoxic amyloid-β (Aβ) aggregation is also a critical event in AD pathology. The development of dual-targeting nanomaterials with antiamyloidosis ability and enzyme-mimicking activity is expected to be a promising strategy for the treatment of amyloidosis and reactive oxygen species-mediated AD progression. Here, bimetallic-peptide framework nanozymes (CuZn-PEP NZs) with amyloid-β (Aβ) attenuating ability, multiple enzyme-mimicking properties, and broad-spectrum reactive oxygen species scavenging capacity were endowed to inhibit Aβ fibrillization, disaggregate Aβ fibrils, and scavenge Aβ fibril-induced reactive oxygen species. An obvious inhibitory effect on Aβ fibrillization and a disaggregation effect on Aβ fibrils were observed after treatment with CuZn-PEP NZs. Meanwhile, the cytotoxicity of Aβ fibrils toward PC12 cells was significantly reduced by CuZn-PEP NZs. Meanwhile, CuZn-PEP NZs with multiple redox pairs exhibit superoxide dismutase, catalase, and glutathione peroxidase-mimicking enzyme properties simultaneously, which further display cytoprotective effects against Aβ fibril-induced reactive oxygen species and mitochondrial damage. Besides, cellular studies verified that CuZn-PEP NZs possess excellent biocompatibility and blood–brain barrier penetration capacity. Overall, these bimetallic-peptide framework nanozymes represent a promising perspective for attenuation of amyloid-β aggregation and reactive oxygen species simultaneously, which highlights the potential of nanozymes for the treatment of amyloidosis and reactive oxygen species-mediated AD progression.
- 28 August 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (9) , 4346-4360
Open AccessA Metal-Peptide Framework as a Nanozyme for the Attenuation of Amyloid-β Aggregation and Reactive Oxygen Species
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by abnormal performance in memory, cognition, and language, and it imposes a heavy economic burden worldwide. Amyloidosis and oxidative stress are highly associated with AD progression, yet limited clinical drugs are available at present. Nanozymes exhibit diverse enzyme-mimetic activities and have attracted widespread attention as a promising alternative candidate for scavenging reactive oxygen species to maintain the oxidation–antioxidation balance in cells. Neurotoxic amyloid-β (Aβ) aggregation is also a critical event in AD pathology. The development of dual-targeting nanomaterials with antiamyloidosis ability and enzyme-mimicking activity is expected to be a promising strategy for the treatment of amyloidosis and reactive oxygen species-mediated AD progression. Here, bimetallic-peptide framework nanozymes (CuZn-PEP NZs) with amyloid-β (Aβ) attenuating ability, multiple enzyme-mimicking properties, and broad-spectrum reactive oxygen species scavenging capacity were endowed to inhibit Aβ fibrillization, disaggregate Aβ fibrils, and scavenge Aβ fibril-induced reactive oxygen species. An obvious inhibitory effect on Aβ fibrillization and a disaggregation effect on Aβ fibrils were observed after treatment with CuZn-PEP NZs. Meanwhile, the cytotoxicity of Aβ fibrils toward PC12 cells was significantly reduced by CuZn-PEP NZs. Meanwhile, CuZn-PEP NZs with multiple redox pairs exhibit superoxide dismutase, catalase, and glutathione peroxidase-mimicking enzyme properties simultaneously, which further display cytoprotective effects against Aβ fibril-induced reactive oxygen species and mitochondrial damage. Besides, cellular studies verified that CuZn-PEP NZs possess excellent biocompatibility and blood–brain barrier penetration capacity. Overall, these bimetallic-peptide framework nanozymes represent a promising perspective for attenuation of amyloid-β aggregation and reactive oxygen species simultaneously, which highlights the potential of nanozymes for the treatment of amyloidosis and reactive oxygen species-mediated AD progression.
- 6 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry A
- Vol. 13 (4) , 2780-2788
A peptide-based conductive hydrogel capable of in situ bioelectrocatalytic NADH regeneration for sustained production of 1-propanol
Nicotinamide-adenine dinucleotide (NAD+/NADH) is a coenzyme that acts as a donor and acceptor of electrons in redox reactions within all eukaryotic cells. The reduction of NAD+ produces NADH that subsequently acts as the key electron carrier. However, limited stability of enzymes under operational conditions, unwanted by-products and limited external electron donors result in low efficiency of NADH regeneration to drive the downstream enzymatic reactions. Herein, we modularly designed a peptide hydrogel, which provided an appropriate physiological microenvironment for maintaining the bioactivity of alcohol dehydrogenase. Meanwhile, Bi nanoparticles were in situ synthesized and doped into nanofibers during the peptide self-assembly to afford a conductive hydrogel with enhanced bioelectrocatalytic efficiency. Both linear sweep voltammetry and chronoamperometry data unveiled excellent electrochemical performance of this hydrogel for sustained NADH regeneration at low potential (−0.37 V vs. RHE). Even at a relatively high potential of −0.79 V vs. RHE, the yield of NADH for 10 h was as high as 81%. The regenerated NADH could further drive propionaldehyde alcoholization to produce 1-propanol sustainably with a rate of 1.34 mM h−1 at −0.62 V (vs. RHE). Overall, this peptide-based conductive hydrogel could achieve sustained 1-propanol production by leveraging in situ bioelectrocatalytic NADH regeneration, demonstrating a promising approach for electroenzymatic biofuel and pharmaceutical production.
- 6 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry A
- Vol. 13 (4) , 2780-2788
A peptide-based conductive hydrogel capable of in situ bioelectrocatalytic NADH regeneration for sustained production of 1-propanol
Nicotinamide-adenine dinucleotide (NAD+/NADH) is a coenzyme that acts as a donor and acceptor of electrons in redox reactions within all eukaryotic cells. The reduction of NAD+ produces NADH that subsequently acts as the key electron carrier. However, limited stability of enzymes under operational conditions, unwanted by-products and limited external electron donors result in low efficiency of NADH regeneration to drive the downstream enzymatic reactions. Herein, we modularly designed a peptide hydrogel, which provided an appropriate physiological microenvironment for maintaining the bioactivity of alcohol dehydrogenase. Meanwhile, Bi nanoparticles were in situ synthesized and doped into nanofibers during the peptide self-assembly to afford a conductive hydrogel with enhanced bioelectrocatalytic efficiency. Both linear sweep voltammetry and chronoamperometry data unveiled excellent electrochemical performance of this hydrogel for sustained NADH regeneration at low potential (−0.37 V vs. RHE). Even at a relatively high potential of −0.79 V vs. RHE, the yield of NADH for 10 h was as high as 81%. The regenerated NADH could further drive propionaldehyde alcoholization to produce 1-propanol sustainably with a rate of 1.34 mM h−1 at −0.62 V (vs. RHE). Overall, this peptide-based conductive hydrogel could achieve sustained 1-propanol production by leveraging in situ bioelectrocatalytic NADH regeneration, demonstrating a promising approach for electroenzymatic biofuel and pharmaceutical production.